Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial (2019)
Attributed to:
CANCER: Trials with potential global reach and other challenging trials
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(19)32259-7
PubMed Identifier: 31791688
Publication URI: http://europepmc.org/abstract/MED/31791688
Type: Journal Article/Review
Parent Publication: The Lancet
Issue: 10214
ISSN: 0140-6736